

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
Participants in population	86	84	84
<b>Cardiac Disorders</b>	<b>13</b>	<b>13</b>	<b>18</b>
Atrial Fibrillation	1	1	3
Atrial Flutter	0	1	1
Atrial Hypertrophy	1	0	0
Atrioventricular Block First Degree	1	1	0
Atrioventricular Block Second Degree	2	0	3
Bradycardia	1	0	0
Bundle Branch Block Left	1	0	0
Bundle Branch Block Right	1	1	0
Cardiac Disorder	0	0	1
Cardiac Failure Congestive	1	0	0
Myocardial Infarction	4	2	4
Palpitations	0	2	0
Sinus Arrhythmia	1	0	0
Sinus Bradycardia	2	7	8
Supraventricular Extrasystoles	1	1	1
Supraventricular Tachycardia	0	1	0
Tachycardia	1	0	0
Ventricular Extrasystoles	0	2	1
Ventricular Hypertrophy	1	0	0
Wolff-Parkinson-White Syndrome	0	1	0
<b>Congenital, Familial and Genetic Disorders</b>	<b>0</b>	<b>1</b>	<b>2</b>
Ventricular Septal Defect	0	1	2
<b>Ear and Labyrinth Disorders</b>	<b>1</b>	<b>2</b>	<b>1</b>
Cerumen Impaction	0	1	0
Ear Pain	1	0	0
Tinnitus	0	1	0
Vertigo	0	1	1
<b>Eye Disorders</b>	<b>4</b>	<b>2</b>	<b>1</b>
Conjunctival Haemorrhage	0	1	0
Conjunctivitis	2	0	0

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>Eye Disorders</b>	<b>4</b>	<b>2</b>	<b>1</b>
Eye Allergy	1	0	0
Eye Pruritus	1	0	0
Eye Swelling	1	0	0
Glaucoma	1	0	0
Vision Blurred	0	1	1
<b>Gastrointestinal Disorders</b>	<b>17</b>	<b>15</b>	<b>21</b>
Abdominal Discomfort	0	0	1
Abdominal Pain	1	3	1
Constipation	1	0	0
Diarrhoea	9	5	4
Dyspepsia	1	1	1
Dysphagia	0	1	0
Flatulence	1	0	0
Gastrointestinal Haemorrhage	0	0	1
Gastrooesophageal Reflux Disease	1	0	0
Glossitis	1	0	0
Hiatus Hernia	1	0	0
Nausea	3	3	6
Rectal Haemorrhage	0	1	0
Salivary Hypersecretion	0	0	4
Stomach Discomfort	0	0	1
Vomiting	3	3	7
<b>General Disorders and Administration Site Conditions</b>	<b>21</b>	<b>47</b>	<b>40</b>
Application Site Bleeding	0	1	0
Application Site Dermatitis	5	9	7
Application Site Desquamation	0	1	0
Application Site Discharge	0	0	1
Application Site Discolouration	0	1	0
Application Site Erythema	3	12	15
Application Site Induration	1	0	0
Application Site Irritation	3	9	9
Application Site Pain	0	0	2
Application Site Perspiration	0	0	2
Application Site Pruritus	6	22	22

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>General Disorders and Administration Site Conditions</b>	<b>21</b>	<b>47</b>	<b>40</b>
Application Site Reaction	1	0	1
Application Site Swelling	0	1	2
Application Site Urticaria	0	2	1
Application Site Vesicles	1	4	6
Application Site Warmth	0	1	0
Asthenia	1	0	1
Chest Discomfort	0	0	2
Chest Pain	0	0	2
Chills	1	1	1
Cyst	0	1	0
Fatigue	1	5	5
Feeling Abnormal	0	0	1
Feeling Cold	0	0	1
Inflammation	0	1	0
Malaise	0	1	2
Oedema	0	2	0
Oedema Peripheral	2	1	2
Pain	0	1	1
Pyrexia	2	0	1
Secretion Discharge	0	1	0
Sudden Death	0	1	0
Swelling	0	1	0
Ulcer	0	1	0
<b>Hepatobiliary Disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>
Hyperbilirubinaemia	1	0	0
<b>Immune System Disorders</b>	<b>0</b>	<b>1</b>	<b>1</b>
Hypersensitivity	0	1	0
Seasonal Allergy	0	0	1
<b>Infections and Infestations</b>	<b>16</b>	<b>10</b>	<b>13</b>
Bronchitis	1	0	0
Cellulitis	0	1	0
Cervicitis	1	0	0
Cystitis	1	0	1
Ear Infection	2	0	0

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>Infections and Infestations</b>	<b>16</b>	<b>10</b>	<b>13</b>
Gastroenteritis Viral	1	0	0
Hordeolum	0	0	1
Influenza	1	1	1
Localised Infection	1	1	0
Lower Respiratory Tract Infection	0	0	1
Nasopharyngitis	2	4	6
Onychomycosis	0	1	0
Pneumonia	0	1	0
Rhinitis	0	0	1
Upper Respiratory Tract Infection	6	1	3
Urinary Tract Infection	2	0	1
Vaginal Mycosis	1	0	0
Viral Infection	0	1	0
<b>Injury, Poisoning and Procedural Complications</b>	<b>4</b>	<b>5</b>	<b>5</b>
Contusion	1	1	2
Excoriation	2	1	1
Facial Bones Fracture	0	0	1
Fall	1	2	1
Hip Fracture	1	0	2
Joint Dislocation	0	1	0
Skin Laceration	1	2	0
Wound	0	1	0
<b>Investigations</b>	<b>10</b>	<b>7</b>	<b>6</b>
Biopsy	0	0	1
Biopsy Prostate	0	0	1
Blood Alkaline Phosphatase Increased	1	0	0
Blood Cholesterol Increased	0	0	1
Blood Creatine Phosphokinase Increased	1	0	0
Blood Glucose Increased	0	1	1
Blood Urine Present	1	0	0
Body Temperature Increased	0	1	0
Cystoscopy	1	0	0
Electrocardiogram St Segment Depression	4	1	0
Electrocardiogram t Wave Amplitude Decreased	1	1	0

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>Investigations</b>	<b>10</b>	<b>7</b>	<b>6</b>
Electrocardiogram t Wave Inversion	2	1	1
Heart Rate Increased	1	0	0
Heart Rate Irregular	1	0	0
Nasal Mucosa Biopsy	0	1	0
Neutrophil Count Increased	0	1	0
Urine Analysis Abnormal	0	1	0
Weight Decreased	0	0	1
White Blood Cell Count Increased	0	1	0
<b>Metabolism and Nutrition Disorders</b>	<b>6</b>	<b>1</b>	<b>3</b>
Decreased Appetite	1	0	1
Dehydration	1	0	0
Diabetes Mellitus	1	0	0
Food Craving	1	1	0
Hypercholesterolaemia	0	0	1
Hyponatraemia	1	0	0
Increased Appetite	1	0	1
<b>Musculoskeletal and Connective Tissue Disorders</b>	<b>5</b>	<b>7</b>	<b>8</b>
Arthralgia	1	2	1
Arthritis	1	0	1
Back Pain	1	1	3
Flank Pain	0	0	2
Muscle Spasms	0	1	1
Muscular Weakness	0	1	0
Myalgia	0	0	1
Pain in Extremity	1	0	0
Shoulder Pain	1	2	0
<b>Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps)</b>	<b>0</b>	<b>2</b>	<b>1</b>
Colon Cancer	0	1	0
Malignant Fibrous Histiocytoma	0	1	0
Prostate Cancer	0	0	1
<b>Nervous System Disorders</b>	<b>12</b>	<b>20</b>	<b>27</b>
Amnesia	0	0	1
Balance Disorder	0	1	0
Burning Sensation	0	0	2

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>Nervous System Disorders</b>	<b>12</b>	<b>20</b>	<b>27</b>
Cognitive Disorder	0	0	1
Complex Partial Seizures	0	1	0
Coordination Abnormal	0	1	0
Dizziness	2	8	12
Headache	7	3	6
Hemianopia Homonymous	0	1	0
Hypersomnia	0	0	1
Lethargy	0	1	1
Paraesthesia	0	0	1
Paraesthesia Oral	0	1	0
Parkinson's Disease	1	0	0
Parosmia	0	0	1
Partial Seizures with Secondary Generalisation	0	0	1
Psychomotor Hyperactivity	1	0	0
Somnolence	2	3	1
Stupor	0	1	0
Syncope	0	4	3
Syncope Vasovagal	0	0	1
Transient Ischaemic Attack	0	2	1
<b>Psychiatric Disorders</b>	<b>10</b>	<b>10</b>	<b>9</b>
Agitation	2	2	1
Anxiety	1	3	0
Completed Suicide	1	0	0
Confusional State	2	3	1
Delirium	0	0	1
Delusion	1	0	1
Depressed Mood	0	1	1
Disorientation	1	0	0
Hallucination	0	0	1
Hallucination, Visual	0	0	1
Insomnia	2	0	2
Irritability	1	1	0
Libido Decreased	0	0	1
Listless	0	0	1

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>Psychiatric Disorders</b>	<b>10</b>	<b>10</b>	<b>9</b>
Nightmare	0	0	1
Restlessness	0	1	0
<b>Renal and Urinary Disorders</b>	<b>4</b>	<b>4</b>	<b>3</b>
Calculus Urethral	0	0	1
Dysuria	1	1	0
Enuresis	0	1	0
Incontinence	0	1	0
Micturition Urgency	1	1	1
Nephrolithiasis	1	0	1
Pollakiuria	1	0	0
<b>Reproductive System and Breast Disorders</b>	<b>2</b>	<b>0</b>	<b>1</b>
Benign Prostatic Hyperplasia	1	0	1
Pelvic Pain	1	0	0
<b>Respiratory, Thoracic and Mediastinal Disorders</b>	<b>10</b>	<b>10</b>	<b>10</b>
Allergic Granulomatous Angiitis	0	0	1
Cough	3	6	5
Dysphonia	0	1	0
Dyspnoea	1	1	1
Emphysema	1	0	0
Epistaxis	0	1	2
Haemoptysis	1	0	0
Nasal Congestion	3	1	3
Pharyngeal Erythema	0	0	1
Pharyngolaryngeal Pain	0	1	1
Postnasal Drip	1	0	0
Productive Cough	0	0	1
Rales	1	0	0
Respiratory Tract Congestion	0	0	1
Rhinorrhoea	0	1	1
<b>Skin and Subcutaneous Tissue Disorders</b>	<b>21</b>	<b>42</b>	<b>42</b>
Actinic Keratosis	0	0	1
Alopecia	1	0	0
Blister	0	5	1
Cold Sweat	1	0	0

Analysis of Participants With Specific Adverse Events  
(Safety Analysis Population)

	Placebo n	Xanomeline Low Dose n	Xanomeline High Dose n
<b>Skin and Subcutaneous Tissue Disorders</b>	<b>21</b>	<b>42</b>	<b>42</b>
Dermatitis Atopic	1	0	0
Dermatitis Contact	0	1	0
Drug Eruption	1	0	0
Erythema	9	15	14
Hyperhidrosis	2	4	8
Pruritus	8	23	26
Pruritus Generalised	0	1	1
Rash	5	13	11
Rash Erythematous	0	2	0
Rash Maculo-Papular	0	0	1
Rash Papular	0	0	1
Rash Pruritic	0	1	2
Skin Exfoliation	0	1	0
Skin Irritation	3	6	5
Skin Odour Abnormal	0	0	1
Skin Ulcer	1	0	0
Urticaria	0	1	1
<b>Social Circumstances</b>	<b>0</b>	<b>0</b>	<b>1</b>
Alcohol Use	0	0	1
<b>Surgical and Medical Procedures</b>	<b>2</b>	<b>1</b>	<b>2</b>
Acrochordon Excision	0	0	1
Cataract Operation	1	1	0
Eye Laser Surgery	1	0	0
Skin Lesion Excision	0	0	1
<b>Vascular Disorders</b>	<b>3</b>	<b>3</b>	<b>2</b>
Hot Flush	0	1	0
Hypertension	1	1	1
Hypotension	2	1	0
Orthostatic Hypotension	1	0	0
Wound Haemorrhage	0	0	1
Every subject is counted a single time for each applicable row and column.			